SCI & TECH● LOW1h ago · Sep 8, 2026, 12:55 PM
Intellia rises on FDA priority review for one-time hereditary angioedema therapy
Seeking Alpha Tech · north america
Intellia's stock has risen after its one-time hereditary angioedema therapy received priority review from the FDA. This indicates a fast-tracked regulatory assessment for a potential new medical treatment.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Sci & Tech
SCI & TECH11m agoDubai launches Agentic AI training drive for 14,000 businessesEuroNews [en]SCI & TECH12m agoBengaluru South Corporation deploys AI cameras to track potholes, garbage dumping, and encroachmentsThe HinduSCI & TECH12m agoNew lichen species discovered in Keralam’s Mathikettan Shola National ParkThe HinduSCI & TECH48m agoAI 80s photos: how to do the viral trend that transforms your photo and the prompt so it doesn't change your faceClarín